USD10
CHRS acciones
Acerca de Coherus OncologyCoherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
USD10
CHRS acciones
Acerca de Coherus OncologyCoherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Estadísticas
VENTANA DE OPERACIÓN
Abierta
CIERRA A LAS
20:00 GMT+0
CAPITALIZACIÓN DE MERCADO
242,07 M US$
PRECIO DE APERTURA
1,55 US$
BAJO (1Y)
0,71 US$
ALTO (1Y)
2,62 US$
BAJO (24H)
1,54 US$
Alza (24H)
1,62 US$
Volumen (24 h)
373,60 mil US$
86,79 %
Historial de precios
Time | Price | Change |
|---|---|---|
Hoy | 1,55 US$ | |
1 día | 1,50 US$ | |
1 semana | 1,66 US$ | |
1 mes | 1,59 US$ | |
1 año | 0,9521 US$ |